Using Indoor Air Filtration to Slow Atherothrombosis Progression in Adults With Ischemic Heart Disease History
Slowing Atherothrombosis Progression Through Indoor Air Filtration: A Crossover Trial in Hispanic and Non-Hispanic Adults With Ischemic Heart Disease History
University of Southern California
112 participants
Jul 11, 2023
INTERVENTIONAL
Conditions
Summary
This double-blind, randomized, crossover trial aims to test the hypothesis that longer-term indoor air filtration intervention can slow atherothrombosis progression by reducing indoor fine particulate matter (PM2.5) exposure in adults with ischemic heart disease history.
Eligibility
Inclusion Criteria6
- Age between 65 and 84 years old;
- Weight ≥ 110 pounds;
- Nonsmokers for at least 1 year;
- Have ischemic heart disease history, clinically stable for 6 months, without any deterioration in symptoms or episodes of angina based on past electronic medical records;
- Both English and Spanish speaking participants will be included in the recruitment;
- Live in the Los Angeles County.
Exclusion Criteria7
- Have history of degenerative disease of the nervous system such as dementia and Alzheimer's;
- Currently have active cancer treatments;
- The residential house has already had HEPA filters;
- Participants will move out from the current residential address in the next 2 years;
- Participants will spend more than 1 month living outside the primary home;
- Have any health conditions that prohibit collecting health and covariate data and biospecimens;
- Participants' residential houses are not feasible for setting up air purifiers and air pollutants monitors.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
HEPA filters with the capacity to reduce PM2.5 levels
Sham filtration use the same appearance of air purifier but with HEPA filter removed.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05867381